5 High Growth Non-Tech Stocks That Are Profitable

2. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Number of Hedge Fund Investors: 55

Baird recently published a list of its top biotech picks for 2024. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was part of the list.

A total of 55 hedge funds in Insider Monkey’s database had stakes in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). The most significant stakeholder of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was Steve Cohen’s Point72 Asset Management which owns a $290 million stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Harding Loevner Global Small Companies Equity Strategy made the following comment about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in its Q3 2023 investor letter:

“By sector, our returns in Health Care were positive but this was more than offset by poor Industrials stocks. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reported positive late-stage clinical study data for its treatment of congenital adrenal hyperplasia, a condition which causes the body to not produce enough cortisol, increasing the probability that the company can address a new estimated $1 billion market opportunity.”